Piper Sandler raised the firm’s price target on Merit Medical (MMSI) to $116 from $114 and keeps an Overweight rating on the shares after the company hosted a call to discuss the commercial opportunity and launch strategy for the WRAPSODY Cell-Impermeable Endoprosthesis, as well as revenue expectations for 2025. Specifically, management is conservatively targeting $7M-$9M in WRAPSODY CIE revenue for 2025, with revenue weighted towards the latter part of the year to account for time needed to clear VACs and secure add-on reimbursement, the firm adds.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $128 from $127 at Canaccord
- Merit Medical Celebrates FDA Approval of WRAPSODY™
- Merit Medical price target raised to $114 from $110 at Piper Sandler
- Merit Medical Systems Reveals Strong 2024 Revenue Growth
- Merit Medical raises FY24 revenue view to $1.355B-$1.357B from $1.344B-$1.352B